Treatment of T3, N3, M0 Lung Cancer

Introduction to Treatment Approaches

The American College of Oncology recommends concurrent chemoradiotherapy as the standard treatment approach for T3, N3, M0 lung cancer, as surgery is contraindicated in N3 disease outside of clinical trials 1, 2, 3

For small cell lung cancer (SCLC) patients with good performance status and T1-4, N0-3, M0 disease, the European Society for Medical Oncology recommends concurrent chemotherapy with thoracic radiotherapy as the standard treatment 1, 4, 5
The chemotherapy regimen for SCLC typically consists of 4 cycles of cisplatin-etoposide, or 4-6 cycles if once-daily radiotherapy is used, as recommended by the European Society for Medical Oncology 1
Twice-daily radiotherapy schedule (1.5 Gy twice-daily, 30 fractions) shows superior 5-year overall survival of 26% versus 16% with once-daily (1.8 Gy, 25 fractions) for SCLC patients, according to the European Society for Medical Oncology 1
The American College of Radiology recommends that thoracic radiotherapy should be initiated as early as possible, beginning with the first or second cycle of cisplatin-based chemotherapy for SCLC patients 1
Prophylactic cranial irradiation (PCI) should be considered for SCLC patients who respond to initial treatment, as recommended by the European Society for Medical Oncology 1, 4
The expected outcomes for SCLC patients are a median survival of 15-20 months, 2-year survival of 20-40%, and 5-year survival of 20-25%, according to the European Society for Medical Oncology 1, 4

The British Thoracic Society states that surgery is absolutely contraindicated in N3 disease outside of prospective clinical trials for NSCLC patients 2, 3
The American College of Chest Physicians recommends definitive concurrent chemoradiotherapy as the treatment for NSCLC patients with T3, N3, M0 disease 6, 7

The British Journal of Cancer recommends that multidisciplinary consultation is mandatory before initiating therapy for lung cancer patients 2, 8
The European Society for Medical Oncology suggests that response evaluation should be performed after 2-3 cycles of chemotherapy by repeating initial radiographic tests for lung cancer patients 9, 10
Close follow-up is essential for lung cancer patients given the aggressive nature of the disease, as recommended by the European Society for Medical Oncology 9, 10